Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Solid Tumor
Phase PHASE1
Enrollment 36
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this study, the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 will be investigated in patients with unresectable locally advanced or metastatic breast cancer and other solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-B01D1 — Administration by intravenous infusion

Primary Outcomes

  • Phase Ia: Dose limiting toxicity (DLT) (Up to 21 days after the first dose)
  • Phase Ib: phase II clinical studies (RP2D) (Up to 21 days after the first dose)
  • Phase Ia: Maximum tolerated dose (MTD) (Up to 21 days after the first dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-08-11
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Principal Investigators:
  • Jiong Wu (PRINCIPAL_INVESTIGATOR) - Fudan University
  • Jian Zhang (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Sa Xiao, PHD
+86-15013238943
xiaosa@baili-pharm.com
Kun Wang
Guangdong Provincial People's Hospital
Jiong Wu, PHD
Fudan University ShangHai Cancer Center
Interventions
  • Drug: BL-B01D1 — Administration by intravenous infusion
Study Locations (2 sites)
Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
Fudan University ShangHai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form and comply with the protocol requirements; 2. No gender restrictions; 3. Age: ≥18 years and ≤75 years; 4. Expected survival time ≥3 months; 5. Histologically and/or cytologically confirmed unresectable locally advanced or metastatic breast cancer and other solid tumors with failed standard treatment, intolerance to standard treatment, no current standard treatment available, or inability to access standard treatment; 6. Enrolled subjects should not have received prior systemic therapy for unresectable locally advanced or recurrent/metastatic triple-negative breast cancer; 7. Agree to provide archived tumor tissue specimens or fresh tissue samples from primary or metastatic lesions within the past 3 years; 8. Must have at least one measurable lesion as defined by RECIST v1.1; 9. ECOG performance status score of 0 or 1; 10. Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0; 11. No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%; 12. Organ function levels must meet the requirements without transfusion or use of any cell growth factors and/or platelet-raising drugs within 14 days before the first dose of the study drug; 13. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × ULN; 14. Urine protein ≤2+ or ≤1000 mg/24h; 15. For premenopausal women with childbearing potential, a pregnancy test (serum or urine) must be performed within 7 days before starting treatment, and the result must be negative; they must not be breastfeeding. All enrolled patients (regardless of gender) must use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends. Exclusion Criteria: 1. Received biological therapy, immunotherapy, or other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs such as tegafur/gimeracil/oteracil (S-1) or capecitabine, or oral endocrine therapy, or palliative radiotherapy within 2 weeks before the first dose); 2. History of severe heart disease; 3. Prolonged QT interval, complete left bundle branch block, third-degree atrioventricular block, or severe arrhythmia; 4. Active autoimmune or inflammatory diseases; 5. Diagnosis of other malignancies within 2 years prior to the first dose; 6. Poorly controlled hypertension (systolic blood pressure \>150 mmHg or diastolic blood pressure \>100 mmHg) despite the use of two antihypertensive medications; 7. Poorly controlled blood glucose (defined as: a) two fasting blood glucose levels \>10 mmol/L, or b) glycated hemoglobin level exceeding 8%), or concurrent diabetic gangrene; 8. History of interstitial lung disease (ILD), current ILD, or suspected ILD based on imaging during screening; 9. Concurrent pulmonary disease leading to clinically significant respiratory impairment; 10. Unstable deep vein thrombosis, arterial thrombosis, pulmonary embolism, or other thrombotic events requiring therapeutic intervention within 6 months before screening (excluding catheter-related thrombosis); 11. Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (leptomeningeal metastases); 12. Patients with significant serous cavity effusion, symptomatic effusion, or poorly controlled effusion; 13. History of hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies, or any excipients of BL-B01D1; 14. Imaging findings indicating tumor invasion or encasement of major thoracic, cervical, or pharyngeal blood vessels, unless the investigator deems it does not affect the patient's eligibility for treatment; 15. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT); 16. Cumulative anthracycline dose \>360 mg/m² in prior (neo)adjuvant anthracycline therapy; 17. Positive for human immunodeficiency virus antibody (HIVAb), active tuberculosis, active hepatitis B virus (HBV) infection, or active hepatitis C virus (HCV) infection; 18. Severe infection (CTCAE \> Grade 2) within 4 weeks before the first dose of the study drug; signs of active pulmonary infection within 2 weeks before the first dose; 19. Participation in another clinical trial within 4 weeks before the first dose (calculated from the last dose date); 20. Any other condition deemed unsuitable for participation in this clinical trial by the investigator.
Conditions Major Depressive Disorder
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an inpatient psychiatric unit. Eligible patients who provided informed consent will be enrolled in the study that will include a eight IV ketamine treatments, 13 esketamine treatment visits, seven long assessment visits, five short assessment visits, and daily surveys. The study will examine the feasibility, tolerability, and efficacy of repeated IV ketamine followed by esketamine, as well as predictors of treatment response.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ketamine — Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
  • Drug: Esketamine — After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.

Primary Outcomes

  • Feasibility - Retention (24 weeks)
  • Feasibility - Drop-out Rates (24 weeks)
  • Tolerability - Cognitive Function and Side Effects (Weeks 0, 1, 2, 3, 4, 8, and 12-24)
  • Tolerability - Dosage of Treatment (Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24)
  • Tolerability - Frequency of Treatment (Change between weeks 0, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-10-13
Completion: 2026-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: American Foundation for Suicide Prevention
Contact Information
Study Contact:
Cristina Cusin, MD
617-724-5510
mghketamindstudy@partners.org
Catherine Schuessler, BS
617-643-7690
mghketamindstudy@partners.org
Catherine Schuessler, BS
617-643-7690
mghketamindstudy@partners.org
Massachusetts General Hospital
Interventions
  • Drug: Ketamine — Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
  • Drug: Esketamine — After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Inpatient at a psychiatric unit (or MGH medical unit, awaiting transfer to psychiatry). 2. Male and female, 18-70 years of age, inclusive, at screening. 3. Diagnosis of MDD, single or recurrent, and currently experiencing a major depressive episode (MDE) at least eight weeks in duration, prior to screening, according to the criteria defined in the Diagnosis and Statistical manual of Mental Disorders, Fifth Edition (DSM-5). The diagnosis of MDD will be made by a site psychiatrist and supported by the Mini-International Neuropsychiatric Interview (MINI). 4. Suicidal ideation determined by a minimum score of 1 on item 12 of the QIDS-C assessment and based on admission to the inpatient unit for suicidal thoughts or behaviors. 5. In good general health, as ascertained by medical history. If needed to verify health status, the investigator may order/conduct physical examination (PE) (including measurement of supine and standing vital signs), clinical laboratory evaluations, or ECG. 6. A status of non-childbearing potential or use of an acceptable form of birth control per the following specific criteria: 1\. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is post-menopausal with her last menses at least one year prior to screening); or 2. Childbearing potential, and meets the following criteria: 1. Childbearing potential, including women using any form of hormonal birth control, on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent. 2. Negative urinary pregnancy test at screening, confirmed by a negative urinary pregnancy test prior to receiving study treatment. 3. Willing and able to continuously use a method of birth control during the course of the study (implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence). The form of birth control will be documented at screening. 7\. Access to a mobile phone or computer with internet connection. 8. Ability to read, understand and provide written and dated informed consent prior to screening. 9\. Must have a provider to manage psychiatric medication, such as a psychiatrist, nurse practitioner, primary care physician, etc., either prior to admission or at discharge from the inpatient unit. Exclusion Criteria: 1. Any history of previous treatment with IV ketamine. 2. Pregnant or breastfeeding. 3. Subject of childbearing potential who is not willing to use birth control during the study. 4. Unstable medical illness, i.e., severe liver or kidney disease, uncontrolled hypertension, uncontrolled hyperthyroidism 5. Current diagnosis of a moderate to severe substance use disorder (excluding mild or moderate alcohol or cannabis use disorder which will be permitted), within the last six months prior to screening based on DSM-5 criteria. 6. History of bipolar disorder, or any psychotic symptoms in the current or previous depressive episodes. 7. An Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening (i.e., eating disorder, OCD, PTSD). 8. Currently receiving ECT treatment. 9. Currently receiving frequent or high dose benzodiazepines, opiates, barbiturates, or other CNS depressant medications, based on an increased risk of sedation in combination with ketamine. 10. Has dementia, delirium, amnestic, or any other primary cognitive disorder. 11. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to a licensed physician on the study staff. 12. Inability to consent to or comply with the study procedures. 13. Other medical issues: 1. Hypertension, (SBP ≥160 mmHg or DBP ≥100 mHg) at Screening - untreated 2. Recent myocardial infarction (within one year) 3. Lifetime history of surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's or Parkinson's Disease), epilepsy, mental retardation, or any other disease/procedure/accident/intervention which, according to the screening done by a licensed physician, is deemed associated with significant injury to or malfunction of the CNS, or history of significant head trauma within the past 2 years 4. Thyroid stimulating hormone (TSH) outside of the normal limits and clinically significant as determined by the Investigator. 5. Any other clinically significant abnormal laboratory result (determined as such by the Investigator and/or medical monitor) at the time of the screening. 6. Patients with diabetes mellitus fulfilling any of the following criteria: 1\. Unstable diabetes mellitus defined as glycosylated hemoglobin (HbA1c) \>8.5% at screening. 2\. Admitted to hospital for treatment of diabetes mellitus or diabetes mellitus- related illness in the past 12 weeks. g. Patients with a history of narrow angle glaucoma - untreated 14. Inability to comply with ketamine clinic safety procedures, including having reliable escorts to and from visits.
Conditions Triple Negative Breast Cancer
Phase PHASE2
Enrollment 86
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Genomically Guided Radiation Therapy — Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
  • Radiation: Genomically Guided Radiation Therapy — Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.

Primary Outcomes

  • Local Control (At 3 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-01-25
Completion: 2029-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Principal Investigators:
  • Kamran Ahmed, MD (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
Contact Information
Study Contact:
Robin Dowell
813-745-0393
Robin.Dowell@moffitt.org
Kamran Ahmed, MD
813-745-3320
Kamran.Ahmed@moffitt.org
Ken Tardif
727-462-3921
Ken.Tardif@baycare.org
Morton Plant Hospital - Baycare Health System
Interventions
  • Radiation: Genomically Guided Radiation Therapy — Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
  • Radiation: Genomically Guided Radiation Therapy — Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
Study Locations (2 sites)
Morton Plant Hospital - Baycare Health System, Clearwater, Florida 33756 United States
Moffitt Cancer Center, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria: * Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection * Confirmation of Triple Negative (TN) breast cancer by tissue biopsy * Adequate tissue to calculate RSI * To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines * To fulfill the requirement of hormone receptor (HR)- disease, a breast cancer must express (\<10%), by immunohistochemistry (IHC), the hormone receptors (estrogen receptor \[ER\] and progesterone receptor \[PR\]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines * Life expectancy \>16 weeks * KPS ≥ 70 * Age ≥ 18 years * Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon * There is no limit on prior systemic therapies * Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study * Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before study enrollment Exclusion Criteria: * Major surgery or significant traumatic injury that has not been recovered from 14 days before study initiation * Women who are pregnant or breastfeeding * Positive surgical margins * History of allergy or hypersensitivity to any of the study drugs or study drug components * Metastatic breast cancer
Conditions Tuberculosis, Acute Coronary Syndrome, P...
Phase PHASE3
Enrollment 150
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD). A recent Phase 2b double-blind randomised-controlled clinical trial shows that adjunctive doxycycline therapy is safe, accelerates resolution of inflammation, suppresses tissue damaging enzyme activity and decreases pulmonary cavity volume (1). We aim to determine if adjunctive doxycycline can reduce PIAT and improve cardiovascular outcomes in a fully powered Phase III trial of 8 weeks of adjunctive doxycycline alongside standard pulmonary TB (PTB) treatment. The investigators hypothesize that doxycycline inhibits tissue destruction in patients with PTB and thereby leads to improved lung function after treatment. Specific aims 1. To assess improvement in lung function as measured by forced expiratory volume (FEV1) predicted in PTB patients given doxycycline versus placebo. 2. To investigate whether doxycycline will hasten the resolution of pulmonary cavities measured by CT thorax 3. To investigate whether doxycycline can suppress inflammatory markers including matrix metalloproteinases 4. To investigate whether doxycycline can accelerate time to sputum conversion 5. To evaluate the effect of doxycycline on cardiovascular outcomes such as the incidence of acute coronary syndrome (ACS) and pulmonary hypertension 6. To investigate whether doxycycline improves TB drug concentrations in sputum and plasma. 7. To assess the safety profile of doxycycline with concurrent standard anti-tuberculous treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Doxycycline — A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
  • Drug: Placebo — Placebo + standard anti-tuberculous treatment

Primary Outcomes

  • Forced expiratory volume in 1 second (FEV1) at 26 weeks measured by spirometry (week 0 to 26)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-05-24
Completion: 2030-01-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University Hospital, Singapore
Collaborators: Tan Tock Seng Hospital, Hospital Queen Elizabeth, Malaysia, National University of Singapore, University Malaysia Sabah, Menggatal Health Clinic, Sabah, Malaysia, Luyang Health Clinic, Sabah, Malaysia
Principal Investigators:
  • Catherine Ong, MRCP PhD (PRINCIPAL_INVESTIGATOR) - National University Hospital, Singapore
Contact Information
Study Contact:
Srishti CHHABRA, MBBS BSc MRCP
+65 6908 2222
srishti.chhabra@mohh.com.sg
Nurul Ain Mohd Yaakub, Dr
nurulainykb@moh.gov.my
Hospital Queen Elizabeth I
Hema Yamini Devi Ramarmuty, Dr
Hospital Queen Elizabeth I
Interventions
  • Drug: Doxycycline — A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
  • Drug: Placebo — Placebo + standard anti-tuberculous treatment
Study Locations (6 sites)
Hospital Queen Elizabeth I, Kota Kinabalu, Sabah Malaysia
Klinik Kesihatan Luyang, Kota Kinabalu, Sabah Malaysia
Klinik Kesihatan Menggatal, Kota Kinabalu, Sabah Malaysia
Universiti Malaysia Sabah (UMS), Borneo Medical and Health Research Centre, Kota Kinabalu, Sabah Malaysia
National University Hospital, Singapore, Singapore 119228 Singapore
TB Control Unit, Singapore, Singapore
Eligibility Criteria
The recruitment target would be 150 patients, with 75 in each arm Inclusion criteria: Patients should meet all criteria: 1. Aged 21 years and above 2. Patients receiving ≤ 14 days of TB treatment or about to start standard combination TB treatment 3. Confirmed pulmonary TB with positive acid-fast bacilli smear and/or positive nucleic acid amplification test (NAAT) and/or TB culture results 4. CXR demonstrating pulmonary involvement with cavity or cavities 5. Able to provide informed consent Exclusion criteria: 1. HIV co-infection 2. Previous pulmonary TB 3. Severe, pre-existing lung disease such as pulmonary fibrosis, bronchiectasis, COPD and lung cancer 4. Pregnant or breast feeding 5. Allergies to tetracyclines 6. Patients on retinoic acid, neuromuscular blocking agents and pimozide which may increase risk of drug toxicity 7. Autoimmune disease and/or on systemic immunosuppressants 8. Use of any investigational or non-registered drug, vaccine or medical device other than the study drug within 182 days preceding dosing of study drug, or planned use during the study period 9. Enrolment in any other clinical trial involving a systemic drug or intervention involving the lung 10. Evidence of severe depression, schizophrenia or mania 11. ALT \> 3 times upper limit of normal 12. Creatinine \> 2 times upper limit of normal 13. Principal investigator assessment of lack of willingness to participate and comply with all requirements including follow-up of the protocol, or identification of any factor felt to significantly increase the participant's risk of suffering an adverse outcome
Conditions Posttraumatic Stress Disorder, Depressio...
Phase NA
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study to learn about patients' experience with the Trauma Resilience and Recovery program (TRRP) and/or the enhanced care group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Trauma Resilience and Recovery Program — The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).

Primary Outcomes

  • Change from Baseline PTSD Checklist for DSM-5 8- item (PCL8-5) at 3-,6-, and 12-month (Baseline, 3-, 6-, and 12- months post-baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-04
Completion: 2027-03-31
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: George Washington University, Agency for Healthcare Research and Quality (AHRQ)
Principal Investigators:
  • Kenneth Ruggiero, PhD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
Gabriela Becerra, BS
8439982602
becerra@musc.edu
Hannah Espeleta, PhD
84377957658
espeleta@musc.edu
Susan Kartiko, MD/PhD
2026776219
skartiko@mfa.gwu.edu
George Washington University Hospital
Interventions
  • Behavioral: Trauma Resilience and Recovery Program — The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
Study Locations (1 sites)
George Washington University Hospital, Washington, Virginia 20037 United States
Eligibility Criteria
Inclusion Criteria: * English- or Spanish-speaking patients ≥ 16 years old who are admitted to George Washington University hospital's trauma center and screen positive on the Injured Trauma Survivors Screen (which indicates risk for development of posttraumatic stress disorder and/or depression) will be included. Exclusion Criteria: * Patients who have a Glasgow Coma Scale score under 13 at hospital admission, moderate to severe cognitive impairment (as measured by the Montreal Cognitive Assessment), active psychosis, or injury that prevents verbal communication (e.g., serious head or spinal cord injury) or is self-inflicted will be excluded. Patients with positive substance use screens via GWU's SBIRT protocol (\~7% of the patient population) will be assessed by the clinical team with reference to severity and recency of substance use problems. We have found at MUSC that a high percentage of patients with SBIRT- positive screens are nevertheless good candidates for TRRP (\>85%), but patients with serious, active substance abuse problems are likely not good candidates for TRRP and therefore will be excluded and referred to a substance use treatment center.
Conditions Chronic Kidney Diseases, Hypertension, D...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Biomarkers — Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.

Primary Outcomes

  • Number of Participants with End Stage Renal Disease (3 years)
  • Number of Participants with Adverse cardiovascular events (3 years)
  • Number of Participants with all cause death (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-07-01
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Principal Investigators:
  • Limeng Chen (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital
Contact Information
Study Contact:
Yan Liu
+86-15811568692
liuyanpumch@163.com
Yan Liu
+86-15811568692
liuyanpumch@163.com
Peking Union Medical College Hospital
Interventions
  • Diagnostic Test: Biomarkers — Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
Study Locations (1 sites)
Peking Union Medical College Hospital, Beijing, Beijing Municipality 100730 China
Eligibility Criteria
Inclusion Criteria: * The diagnosis of metabolic diseases were confirmed; * Be able to understand the process of the research; * Volunteer for participation and be able to sign the informed consent. Exclusion Criteria: * Age \<18 yrs or \>80yrs; * Patients with primary and secondary glomerular diseases * Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors; * Contraindications for MRI examination; * Pregnant or lactation patients; * Patients with unstable vital signs, failure of other organs or dysphoria.
Conditions Salt; Excess, Hypertension
Phase NA
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs the ability of systemic blood vessels and the kidneys to control blood pressure, which contributes to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. There is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. However, limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could allow us to determine novel therapeutic targets to combat high salt.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: No Salt, No β-OHB — Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
  • Dietary Supplement: High Salt, No β-OHB — Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
  • Dietary Supplement: High Salt, High β-OHB — Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).

Primary Outcomes

  • Resting blood pressure (This measure is completed on day 10 of each 10-day intervention (low salt, high salt, high salt+ ketone) over 3-4 months and values will be compared across interventions.)
  • Blood pressure reactivity responses (This measure is completed on day 10 of each 10-day intervention (low salt, high salt, high salt+ ketone) over 3-4 months and values will be compared across interventions.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-24
Completion: 2027-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: true
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Indiana University
Collaborators: University of Utah, University of Missouri-Columbia
Principal Investigators:
  • Austin T Robinson, PhD (PRINCIPAL_INVESTIGATOR) - Indiana University
Contact Information
Study Contact:
Austin T Robinson, PhD
5745141034
ausrobin@iu.edu
Kallie E Dawkins, MS
8505566251
kaldawki@iu.edu
Austin T Robinson, PhD
574-514-1034
ausrobin@iu.edu
Indiana University, School of Public Health
Interventions
  • Dietary Supplement: No Salt, No β-OHB — Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
  • Dietary Supplement: High Salt, No β-OHB — Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
  • Dietary Supplement: High Salt, High β-OHB — Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
Study Locations (1 sites)
Indiana University, School of Public Health, Bloomington, Indiana 47405 United States
Eligibility Criteria
Inclusion Criteria: * Between the ages of 19-39 * Resting blood pressure no higher than 150/90 * BMI below 35 kg/m2 (or otherwise healthy) * Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, \& cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular) * Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle/joint issues including painful arthritis) or giving blood (e.g., blood thinners). Exclusion Criteria: * High blood pressure - greater than 150/90 mmHg * Obesity (BMI \> 30 kg/m2) * History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular). * Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle/joint issues including painful arthritis) * Medical issues that prevent giving blood (e.g., blood thinners). * Current smoking, using smokeless tobacco, or vaping (within past 12 months) * Current pregnancy
Conditions Alopecia, Chemotherapy-induced Alopecia,...
Phase NA
Enrollment 99
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: AMMA Portalbe Scalp Cooling System — AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.

Primary Outcomes

  • Hair Loss (3 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-08
Completion: 2026-09-30
Eligibility
Age: 21 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 99 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cooler Heads Care Inc.
Principal Investigators:
  • Kate Dilligan (PRINCIPAL_INVESTIGATOR) - Cooler Heads Inc.
Contact Information
Study Contact:
Chris Schultz, BS
9715067552
cschultz@ecr-inc.com
Sima Ehsani, MD
520-621-2449
simaehsani@arizona.edu
University of Arizona
Maria Perdekamp, MD
217-300-5700
Maria.Grosse-Perdekamp@carle.com
Carle Health
Interventions
  • Device: AMMA Portalbe Scalp Cooling System — AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
Study Locations (2 sites)
University of Arizona, Tucson, Arizona 245024 United States
Carle Health, Urbana, Illinois 61801 United States
Eligibility Criteria
Inclusion Criteria: 1. Female patients ≥ 21 years of age 2. Documented diagnosis of breast cancer, stage I, II, or III 3. A planned taxane-containing CT regimen in the adjuvant or neoadjuvant setting with curative intent 4. Concomitant agents may include trastuzumab, pertuzumab, or other CT agents such as cyclophosphamide, or carboplatin Note: Targeted and/or hormonal therapies intended for use after completion of the taxane-containing CT regimen will not be considered part of the study treatment period, and the AMMA PSCS will not be used during the post-CT targeted and/or hormonal therapy period 5. Plan to complete the current CT regimen within six months 6. At least two years out from the last CT causing hair loss with complete recovery of hair 7. Karnofsky17 performance status 80% or greater 8. Willing and able to sign informed consent for this study 9. Willing and able to complete all required study procedures Exclusion Criteria: 1. Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale 2. Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss, others 3. A history of whole brain radiation 4. Plans to use a CT regimen other than those specified in the inclusion criteria; specifically, a regimen not including paclitaxel or docetaxel or a regimen including an anthracycline (AC/T, EC/T, TAC, etc.) 5. Hormone therapy concurrent with CT. Hormone therapy after CT is permitted 6. Current and/or prior use of hair growth products, such as Nutrafol, minoxidil, and Keranique 7. A serious concurrent infection or medical illness which would jeopardize the ability of the patient to complete the planned therapy and follow-up 8. History of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens 9. History of and/or current exposure to other agents, drugs, device, or procedure that may cause hair loss 10. Cold sensitivity 11. Intercurrent life-threatening malignancy 12. Evidence of untreated or poorly controlled hyperthyroidism or hypothyroidism 13. History or current diagnosis of any of the following: Cold agglutinin disease, cryoglobulinemia, or cryofibrinogenemia 14. Concurrent hematologic malignancy 15. Participation in any other clinical investigation 16. Concurrent treatment with any investigational agent 17. Any reason the investigator does not believe the patient is a good candidate for the study
Conditions Rumination, Major Depressive Disorder, A...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The research study is being conducted to study brain patterns of negative emotion and develop personalized brain stimulation protocols to disrupt these patterns with transcranial magnetic stimulation (TMS). First, the investigators will use functional Magnetic Resonance Imaging (fMRI) data to generate a negative affect map for each participant. Then, the investigators will apply a variety of repetitive transcranial magnetic stimulation (rTMS) sequences while the participant is inside the MRI scanner to determine the optimal and least optimal rTMS frequencies at changing negative affect brain states. Finally, these two frequencies will be tested over two 3-day rTMS neuromodulation sessions to assess whether they can reduce negative emotions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Device: Transcranial Magnetic Stimulation — Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.

Primary Outcomes

  • Change in ruminative response scale (RRS) score after using the optimal rTMS stimulation frequency vs the least optimal rTMS stimulation frequency (Up to 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-21
Completion: 2029-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pennsylvania
Principal Investigators:
  • Desmond Oathes, PhD (PRINCIPAL_INVESTIGATOR) - Associate Professor of Psychiatry
Contact Information
Study Contact:
Camille Blaine
215-573-0828
camille.blaine@pennmedicine.upenn.edu
Almaris Figueroa-Gonzalez
215-746-6751
almaris.figueroa-gonzalez@pennmedicine.upenn.edu
Camille Blaine
215-573-0828
camille.blaine@pennmedicine.upenn.edu
University of Pennsylvania
Interventions
  • Device: Transcranial Magnetic Stimulation — Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
Study Locations (1 sites)
University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion criteria: 1. 18-65 years old 2. Patient Health Questionnaire (PHQ-9 score) = or \> than 10 3. Comprehension of instructions in the English language. 4. Capacity to provide informed consent and follow study procedures. 5. Availability for the duration of the study. Exclusion Criteria: 1. Diagnosis of bipolar disorder (as PI discretion), schizophrenia or other psychotic disorder 2. Recent use of psychoactive medications or substances as determined by investigators 3. History of neurological disorder or traumatic brain injury (other than mild) 4. Unable to have an MRI scan, or current or prior medical condition that could interfere with the collection or interpretation of MRI data 5. Unable to receive or tolerate TMS 6. Implanted devices, such as an aneurysm clip or cardiac pacemaker 7. History of stroke, epilepsy, or brain scarring 8. Pregnant, nursing, or trying to become pregnant (self-attestation alone) During this study, participants are asked to: 1. Refrain from substance use (including marijuana and illicit drugs) for duration of the study (self-attestation alone). 2. Abstain from alcohol for 24 hours before the MRI scans (self-attestation alone). 3. Abstain from increasing caffeine intake or begin taking any new medications (self-attestation alone).
Conditions Treatment Resistant Depression, Epilepsy
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall goal of this study is to map the spatiotemporal dynamics of social affective processing and to examine selective modulation of these dynamics in humans undergoing invasive intracranial monitoring for treatment-resistant epilepsy and depression. Pursuing this signal from a novel platform with invasive intracranial recording electrodes provides much-needed spatial and temporal resolution to characterize the neural dynamics of socio-affective processing. The investigators will leverage first-in-human intracranial neural recording opportunities created by a novel therapeutic platform termed "stereotactic electroencephalography-informed deep brain stimulation" (stereo-EEG-informed DBS), as well as the powerful platform of intracranial stereotactic recording and stimulation in patients undergoing epilepsy surgical evaluation at Baylor College of Medicine. The sEEG-informed DBS trial provides unique opportunities for intracranial recording of affect-relevant network regions in patients with treatment-resistant depression (TRD). Recordings in identical regions in epilepsy patients who themselves often demonstrate mild-moderate depressive symptoms will provide a wide dynamic range across the symptom spectrum. To provide critical data on the spatiotemporal dynamics of socio-affective processing the investigators will leverage these two human intracranial recording and stimulation cohorts to study the precise structural, functional, and causal properties of the affective salience network. Greater understanding of the social processing circuitry mediated by the affective salience network may be used to drive therapeutic innovation, pioneering a new paradigm that improves socio-emotional function across a wide variety of neuropsychiatric conditions. The results from this proposal have the potential to improve the lives of patients with dysfunction in social affective processing, with implications for a wide range of neuropsychiatric diseases.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: Device: Directional Deep Brain Stimulation — Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation

Primary Outcomes

  • Number of streamlines connecting between intracranial stimulation volume and recording volumes. (up to 8 weeks)
  • Evoked potentials arising from stimulation. (up to 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-01
Completion: 2027-03-31
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: true
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor College of Medicine
Contact Information
Study Contact:
Kelly Bijanki, PhD
713-798-5060
bijanki@bcm.edu
Kelly Bijanki
713-798-5060
bijanki@bcm.edu
Baylor College of Medicine
Interventions
  • Device: Device: Directional Deep Brain Stimulation — Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
Study Locations (1 sites)
Baylor College of Medicine, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Men and women (non-pregnant) between ages 22 and 70; 2. DSM-5 diagnosis (assessed by Structured Clinical Interview for DSM-5 Axis I disorders SCID-5) of major depression disorder (MDD) as the primary diagnosis. A current major depressive episode (MDE), recurrent or single episode with first episode before age 60, secondary to nonpsychotic unipolar major depressive disorder; 3. Chronic illness with current MDE ≥24 months duration and/or recurrent illness with at least a total of 2 lifetime episodes (including current episode \>12 months); 4. Treatment resistance (defined by criteria on the Antidepressant Treatment History Form ATHF): Failure (i.e. persistence of the major depressive episode) to respond to a minimum of four adequate depression treatments from at least two different treatment categories (e.g. SSRIs, SNRIs, TCAs, other antidepressants, lithium-addition, irreversible MAOIs, antidepressant augmentation with an atypical antipsychotic medication); 5. Previous trial of Electroconvulsive Therapy (ECT) (lifetime): either did not respond, relapsed, poorly tolerated or refused. If refused, will discuss reasons and ensure subject understands relative risks of ECT versus DBS. We will try to enrich sample with patients who had previously shown response to ECT (or another intervention) that was partial or un-sustained; 6. Symptom severity for Screening: Hamilton Depression Rating Scale-17 item (HDRS17) ≥20; 7. The HDRS17 must remain greater than or equal to 20 on two separate assessments (at initial screening and 1 week before surgery), over a 1-month period; 8. Symptom severity for Outcome: Montgomery Asberg Rating Scale (MADRS) ≥27 to be met at assessment one-week pre-op; 9. Lifetime exposure to minimal 6 weeks of psychotherapy without sustained response; 10. Must have a brain MRI within 3 months of enrollment that is "normal", according to the radiology report, or does not reveal any findings that in the opinion of the Investigator preclude participation in the study; 11. Stable antidepressant medication regimen for the month preceding surgery; 12. Modified mini-mental state examination (MMSE) score ≥ 24; 13. Normal thyroid stimulating hormone (TSH) level within 12 months of study entry; 14. The patient does not have any medical or physical conditions which, in the opinion of the Investigator, make it unlikely the patient will be able to participate for the duration of the study; 15. Able and willing to give informed consent and agree to attend regular clinic visits for at least 12 months following surgery; 16. Must have a treating psychiatrist, a family member, significant other/living partner, a caregiver, or a person known by the subject present at the Screening visit for the discussion about the study before co-signing the informed consent form; 17. Willingness to sign Treatment Contract; 18. Agrees to be followed at regular intervals by a licensed psychiatrist and to provide written permission allowing any and all forms of communication between the research team and the subject's healthcare providers, for the entirety of the study; 19. Both male and female patients who undergo placement of intracranial electrodes for clinical characterization of epilepsy. Exclusion Criteria: 1. DSM-5 Axis I Disorders: any lifetime history of psychotic disorder (e.g., schizophrenia, schizoaffective disorder); 2. Bipolar disorder with rapid cycling and history of manic episode requiring hospitalization within the past 5 years; 3. Clinically significant Cluster A or B personality disorder; 4. Alcohol or substance use disorder within 6 months, excluding nicotine; 5. Urine drug test positive for illicit drugs; 6. Any evidence or indication of suicidal intent, suicidal attempt, or suicidal behavior, including but not limited to the C-SSRS score, within the past one year; 7. Neurological/Medical condition that makes the patient, in the opinion of the surgeon, a poor surgical candidate (e.g., progressive neurodegenerative disorder, significant cardiopulmonary disorder, need for chronic anticoagulation); 8. Any history of seizure disorder, hemorrhagic stroke, or has high risk of seizure (history of congenital brain malformation, history of brain injury, neuro-developmental disorder, currently taking medication that is known to lower seizure threshold, or other factors that predispose seizures); 9. Any medical contraindication to surgery such as infection; 10. Coagulopathy: Bleeding propensity and/or one of the following: INR \> 1.5; prolonged activated partial thromboplastin time (aPTT) ≥ 45 sec; platelet count \< 100×103/uL; 11. A blood pressure of ≥ 180/110 mmHg at a single visit and evidence of cardiovascular disease (CVD); 12. Participation in another drug, device, or biological trial within 90 days; 13. Current implanted stimulation devices including cardiac pacemakers, defibrillators, and neurostimulators including spinal cord stimulators and deep brain stimulators; 14. Pregnant or has plans to become pregnant in the next 24 months; 15. Anticipated need for MRI; 16. Need for Diathermy; 17. Chronic use of anticoagulant or anti-platelet agents that cannot be safely stopped for a sufficient duration (minimum 2.5 weeks) in the peri-operative period. 18. Any Psychiatric/Neurological/Medical condition that makes the subject, in the opinion of the Investigator, a poor candidate.
Conditions Depression, Unipolar, Pain, Postoperativ...
Phase NA
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase I clinical trial tests the feasibility and safety of a self-guided, mobile mindfulness-based intervention to reduce post-cesarean pain and prevent postpartum depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mindfulness — Meditation training to help reduce stress and reactivity to pain and other stressors.

Primary Outcomes

  • Post-operative pain (1 week postpartum and 8 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-01
Completion: 2028-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Urbana-Champaign
Collaborators: Southern Illinois University, Arrowhead Regional Medical Center, University of Utah
Contact Information
Study Contact:
Sandraluz Lara-Cinisomo, Ph.D.
217-300-3512
laracini@illinois.edu
Sandraluz Lara-Cinisomo, Ph.D
217-300-3512
laracini@illinois.edu
University of Illinois Urbana-Champaign
Interventions
  • Behavioral: Mindfulness — Meditation training to help reduce stress and reactivity to pain and other stressors.
Study Locations (1 sites)
University of Illinois Urbana-Champaign, Champaign, Illinois 61820 United States
Eligibility Criteria
1. Women must self-identify as Latina/Latinx/Hispanic, Asian, African American, or non-Hispanic White. 2. Scheduled to undergo a planned cesarean delivery. 3. Be of 18-45 years of age 4. Have a singleton pregnancy 5. Score between 5 and 13 on the Edinburgh Postnatal Depression Scale (EPDS) 6. A history of depression 7. Have no chronic pain condition (e.g., fibromyalgia) 8. Own a computer, smartphone, or tablet 9. Have a reliable internet access to complete the online surveys. 10. Be proficient in English or Spanish.
Conditions Triple Negative Breast Cancer, Chemother...
Phase PHASE2
Enrollment 26
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Introduction: Most cases of Triple Negative Breast Cancer (TNBC) have a high proliferation rate. TNBC is associated with a poor prognosis, a high recurrence rate, and a high incidence of distant metastases. The Epithelial-Mesenchymal Transition process (EMT) plays an essential role in the metastatic process. EMT markers were also more abundant in TNBC and contributed to a poorer TNBC prognosis. As an important EMT marker, the increased expression of vimentin also contributed to the increase in TNBC aggressiveness and resistance to chemotherapeutic agents. Through the mechanism of action in inhibiting the mevalonate pathway, statins can help inhibit the EMT process in metastases. Notably, simvastatin promotes the down-regulation of vimentin in breast cancer cells. The combination of statins and neoadjuvant chemotherapy (NAC) improves the cancer patient's response. This study is expected to evaluate the role of a combination between NAC and simvastatin on therapeutic response in TNBC patients through vimentin expression. Methods: This study is a double-blind, randomized, placebo-controlled trial conducted in Dr. Cipto Mangunkusumo National Central General Hospital. An expected total of 26 TNBC patients will be assessed for eligibility and asked for informed consent. Patients with the plan to have ACT (Doxorubicin hydrochloride, Cyclophosphamide, Paclitaxel) chemotherapy regimen will receive either a combination of ACT-Simvastatin (40 mg/day) or ACT-Placebo. The biopsy will be taken pre-NAC to make the histopathological diagnosis and examine the expression of vimentin. Patients will be evaluated for adverse effects reaction every cycle and the clinical response after 8 cycles. The post-intervention biopsy will be conducted after the cycle finish. The pathological response and vimentin expression will be reviewed from the obtained samples.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Simvastatin 40mg — The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
  • Drug: Placebo — The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy

Primary Outcomes

  • Vimentin Expression (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-08-19
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitas Indonesia
Principal Investigators:
  • Erwin D Yulian, MD (PRINCIPAL_INVESTIGATOR) - Surgical Oncology Division, Department of Surgery, Universitas Indonesia
  • Tantri Hellyanti, MD (STUDY_DIRECTOR) - Department of Pathological Anatomy, Universitas Indonesia
  • Shabrina Adzania, MD (STUDY_CHAIR) - Research Assistant, Department of Surgery, Universitas Indonesia
Contact Information
Study Contact:
Erwin D Yulian, MD
+6281315249627
erwin.yulian@ui.ac.id
Erwin D Yulian, MD
+6281315249627
Dr. Cipto Mangunkusumo National Central General Hospital
Interventions
  • Drug: Simvastatin 40mg — The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
  • Drug: Placebo — The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Study Locations (1 sites)
Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta Pusat, DKI Jakarta 10430 Indonesia
Eligibility Criteria
Inclusion Criteria: 1. Female patients with advanced breast cancer (locally advanced and distantly advanced) with triple-negative molecular type confirmed by biopsy and immunohistochemical examination. 2. The patient planned to receive 8 cycles of AC-T chemotherapy. 3. Patient age \> 18 years. 4. Willing to participate in research by signing informed consent. Exclusion Criteria: 1. The patient is pregnant or breastfeeding. 2. Patients who have received chemotherapy or are on simvastatin therapy. 3. Allergy to statins.